FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,900 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $54.45, for a total transaction of $1,029,105.00. Following the completion of the sale, the chief executive officer now owns 3,217,455 shares of the company’s stock, valued at approximately $175,190,424.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

FibroGen, Inc (FGEN) traded up 7.23% during mid-day trading on Wednesday, hitting $60.10. 2,814,728 shares of the stock were exchanged. The stock’s 50-day moving average is $48.38 and its 200 day moving average is $34.57. The company’s market capitalization is $4.28 billion. FibroGen, Inc has a 52 week low of $15.60 and a 52 week high of $60.15.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). The company had revenue of $29.00 million during the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. On average, analysts anticipate that FibroGen, Inc will post ($1.80) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/04/fibrogen-inc-fgen-ceo-sells-1029105-00-in-stock.html.

A number of brokerages have commented on FGEN. Citigroup Inc. increased their price target on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research note on Tuesday, August 8th. Mizuho began coverage on shares of FibroGen in a research note on Wednesday. They issued a “neutral” rating for the company. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Stifel Nicolaus reiterated a “buy” rating and issued a $80.00 price target on shares of FibroGen in a research note on Thursday, September 14th. Finally, William Blair reiterated an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $60.17.

Large investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. purchased a new position in shares of FibroGen in the 1st quarter worth about $111,000. Quantbot Technologies LP purchased a new position in shares of FibroGen in the 2nd quarter worth about $128,000. SG Americas Securities LLC boosted its holdings in shares of FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 412 shares during the last quarter. Amalgamated Bank purchased a new position in shares of FibroGen in the 2nd quarter worth about $237,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of FibroGen by 589.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 6,327 shares during the last quarter. 47.49% of the stock is currently owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.